electroCore Announces New Patent for Stroke and TIA Treatment
13 Dezembro 2021 - 10:55AM
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a
commercial-stage bioelectronic medicine company, today announced
that the United States Patent and Trademark Office (USPTO) has
issued U.S. Patent No. 11,191,953 to the Company, relating to the
treatment of stroke symptoms.
The newly issued patent is related to methods for treating the
acute symptoms of stroke or transient ischemic attack (TIA), a
temporary period of symptoms similar to those of a stroke,
according to a treatment paradigm based on the application of a
transcutaneous, non-invasive electrical impulse or stimulation.
This newly allowed patent is owned by the Company and reinforces
development efforts associated with certain investigator-initiated
trials in the area of stroke which is the second highest cause of
death and third leading cause of disability globally. Earlier this
year, the Company announced full enrollment of the TR-VENUS study
of non-invasive vagal nerve stimulation (nVNS) for the acute
treatment of stroke. “We are pleased with this latest patent
issuance relating to another potential important use of
electroCore’s non-invasive approach to treating patients with vagus
nerve stimulation that has devastating impacts on people’s lives,”
commented JP Errico, a founder, board member and investor of the
Company, who was also a co-inventor of the new patent. “Every year,
roughly 15 million people worldwide suffer strokes, and our
non-invasive vagus nerve stimulator technology may be an effective
acute treatment to reduce the damaging effects to the brains of
these patients. With ongoing investigator-initiated trials in
stroke, and our newly issued patent, we look forward to
understanding nVNS’s potential role in the treatment paradigm for
stroke patients worldwide.”About electroCore,
Inc.electroCore, Inc. is a commercial stage bioelectronic
medicine company dedicated to improving patient outcomes through
its non-invasive vagus nerve stimulation therapy platform,
initially focused on the treatment of multiple conditions in
neurology. The company's current indications are the preventive
treatment of cluster headache and migraine, the acute treatment of
migraine and episodic cluster headache, the acute and preventive
treatment of migraines in adolescents, and paroxysmal hemicrania
and hemicrania continua in adults.
For more information, visit www.electrocore.com.
About
gammaCoreTMgammaCoreTM (nVNS) is
the first non-invasive, hand-held medical therapy applied at the
neck as an adjunctive therapy to treat migraine and cluster
headache through the utilization of a mild electrical stimulation
to the vagus nerve that passes through the skin. Designed as a
portable, easy-to-use technology, gammaCore can be
self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore (nVNS) is FDA cleared in the United States for
adjunctive use for the preventive treatment of cluster headache in
adult patients, the acute treatment of pain associated with
episodic cluster headache in adult patients, and the acute and
preventive treatment of migraine in adolescent (ages 12 and older)
and adult patients, and paroxysmal hemicrania and hemicrania
continua in adult patients. gammaCore is CE-marked in the European
Union for the acute and/or prophylactic treatment of primary
headache (Migraine, Cluster Headache, Trigeminal Autonomic
Cephalalgias and Hemicrania Continua) and Medication Overuse
Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been evaluated in the
following patients:
- Adolescent patients with congenital cardiac issues
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
Please refer to the gammaCore Instructions for Use for all of
the important warnings and precautions before using or prescribing
this product.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents providing expanded IP coverage; the
possibility of future business models and revenue streams from the
company’s potential utilizing nVNS for symptoms associated with
acute stroke or TIA, the potential of nVNS generally and gammaCore
in particular and other statements that are not historical in
nature, particularly those that utilize terminology such as
"anticipates," "will," "expects," "believes," "intends," other
words of similar meaning, derivations of such words and the use of
future dates. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue electroCore’s business and
product development plans, the inherent uncertainties associated
with developing new products or technologies, the ability to
commercialize gammaCore™, the potential impact and effects of
COVID-19 on the business of electroCore, electroCore’s results of
operations and financial performance, and any measures electroCore
has and may take in response to COVID-19 and any expectations
electroCore may have with respect thereto, competition in the
industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024